A milestone for us, and a strategic advantage for you as federal rules shift.
DEA registration places SC Labs within a select tier of cannabis and hemp testing laboratories that operate under federal compliance standards.
Earning the registration requires rigorous evaluation of a facility’s practices, personnel, and chain-of-custody protocols. It reflects the depth of commitment that we have made in scientific infrastructure and the seriousness in which we approach our role as your trusted testing partner.
The landscape is shifting
We’re grateful to receive it just in time, too. Effective April 28, 2026, a DEA Final order moved state-licensed medical marijuana from Schedule I to Schedule III of the Controlled Substances Act. This was a landmark shift in federal drug policy and is already reshaping compliance expectations across the industry. An expedited hearing on whether marijuana as a whole, including adult-use cannabis, follows the same path concluded on July 15 after more than two weeks of testimony. The presiding judge’s recommendation is expected following a post-hearing briefing period that runs through August 17.
State-licensed operators face a new set of federal obligations alongside potential opportunity – and the testing partners they rely on will need to meet them at that next level. SC Labs’ DEA registration reflects that readiness.
What’s Next
The details of rescheduling matter enormously, and the regulatory picture will continue to evolve through the summer and beyond. SC Labs will follow these developments closely, share our perspective on what they mean for our partners and the markets that we serve together.
This is a pivotal moment for the cannabis industry. We intend to meet it fully prepared along your side.